Suchergebnisse - "Böttcher, Sebastian"

PubPharm (151)

1

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

enthalten in: Blood advances | 2024

von Stilgenbauer, S. | Tausch, E. | Roberts, A. | +19

2

Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL : Final efficacy and ctDNA analysis of the CLL2-BAAG trial

enthalten in: Blood | 2024

von Fürstenau, M. | Giza, A. | Weiss, J. | +22

3

Nerve injuries due to fractures in childhood : Primarily and secondarily on the upper extremity

enthalten in: Unfallchirurgie (Heidelberg, Germany) | 2024

von Böttcher, R. | Dähne, F. | Böttcher, S. | +3

4

Nervenverletzungen bei Frakturen im Kindesalter

enthalten in: Die Unfallchirurgie | 2024

von Böttcher, R. | Dähne, F. | Böttcher, S. | +3

5

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features : a phase 1/2 trial of the European MCL network (SAKK 36/13)

enthalten in: EClinicalMedicine | 2023

von Novak, U. | Fehr, M. | Schär, S. | +21

6

Final analysis of the CLL2-GIVe trial : obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

enthalten in: Blood | 2023

von Huber, H. | Tausch, E. | Schneider, C. | +22

CommentIn: Blood. 2023 Sep 14;142(11):941-943. - PMID 37707873

7

Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia

enthalten in: Blood advances | 2023

von Engelmann, R. | Jaekel, N. | Jotschke, S. | +9

8

Methods, reagents and kits for detecting minimal residual disease

enthalten in: Europäisches Patentamt | 2023

von VAN DONGEN JACOBUS JOHANNES MARIA | ORFAO DE MATOS CORREIA E VALE JOSÉ ALBERTO | FLORES MONTERO JUAN ALEJANDRO | +8

9

Detecting epileptic seizures with multimodal non-EEG data from wearables

Erschienen: Dissertation, Siegen, Universität Siegen, 2023

von Böttcher, S. | Van Laerhoven, K.

10

Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients

enthalten in: Leukemia & lymphoma | 2023

von Kutsch, N. | Holmes, E. | Robrecht, S. | +14

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[16]